Authors
Latest:
AI and Changing the Future of Pancreatic Cancer ScreeningIn an era where medical records are digitalized, artificial intelligence has the potential to identify patterns that can locate at-risk patients with pancreatic cancer.
Latest:
An Embarrassment of Riches Treatment Sequencing in Gastrointestinal CancersLaura W. Goff, MD, MSCI, MMHC, discusses the onslaught of treatment sequencing available in gastrointestinal cancer.
Latest:
Safeguarding Vulnerability: COVID-19’s Impact on Immunocompromised Patients With CancerImmunocompromised individuals face ongoing COVID-19 risks despite vaccination, highlighting the need for tailored public health strategies and innovative therapies.
Latest:
CDK4/6 Inhibitor Use May Expand in HR+ HER2– Breast CancerDaniel G. Stover, MD, describes how findings from the phase 3 NATALEE trial may support expanding the portion of patients who receive CDK 4/6 inhibitors as a treatment for hormone receptor–positive, HER2-negative breast cancer.
Latest:
Bispecifics in R/R MM: Key TakeawaysPanelists discuss how their key takeaways emphasize the importance of communication and collaboration between academic centers and community practices to ensure equitable access to bispecific therapies, highlighting that it’s an exciting time in myeloma treatment with patient-friendly options that can be administered closer to home, and concluding that virtually no patient should be denied exposure to bispecific therapy before discontinuing treatment, while anticipating that de-escalated Q4 weekly schedules and trispecific agents will transform current practice patterns in the coming years.
Latest:
Cross Q&A: The Memorial Sloan-Kettering MavericksThe Moffitt Marrowvingians take their turn questioning the Memorial Sloan Kettering Mavericks on their presented clinical trial data.
Latest:
Safeguarding Vulnerability: COVID-19’s Impact on Immunocompromised Patients With CancerImmunocompromised individuals face ongoing COVID-19 risks despite vaccination, highlighting the need for tailored public health strategies and innovative therapies.
Latest:
ABBV-400 Shows Early Promise in Pretreated, Metastatic Colorectal Cancer“It does appear like MET expression could be one of the mechanisms wherein you could differentiate between responders and non-responders,” Kanwal P.S. Raghav, MBBS, MD, stated.
Latest:
Future Therapies for ALK+ Metastatic NSCLCDr. Kim shares her insights on new investigational therapies for metastatic ALK+ NSCLC that she's particularly excited about.
Latest:
Precision Medicine in NSCLC The Power of Molecular TestingPersonalized therapy for non–small cell lung cancer has evolved significantly with the advent of comprehensive molecular testing.
